Treatment and Prevention of Depression

2002 ◽  
Vol 3 (2) ◽  
pp. 39-77 ◽  
Author(s):  
Steven D. Hollon ◽  
Michael E. Thase ◽  
John C. Markowitz

Depression is one of the most common and debilitating psychiatric disorders and is a leading cause of suicide. Most people who become depressed will have multiple episodes, and some depressions are chronic. Persons with bipolar disorder will also have manic or hypomanic episodes. Given the recurrent nature of the disorder, it is important not just to treat the acute episode, but also to protect against its return and the onset of subsequent episodes. Several types of interventions have been shown to be efficacious in treating depression. The antidepressant medications are relatively safe and work for many patients, but there is no evidence that they reduce risk of recurrence once their use is terminated. The different medication classes are roughly comparable in efficacy, although some are easier to tolerate than are others. About half of all patients will respond to a given medication, and many of those who do not will respond to some other agent or to a combination of medications. Electro-convulsive therapy is particularly effective for the most severe and resistant depressions, but raises concerns about possible deleterious effects on memory and cognition. It is rarely used until a number of different medications have been tried. Although it is still unclear whether traditional psychodynamic approaches are effective in treating depression, interpersonal psychotherapy (IPT) has fared well in controlled comparisons with medications and other types of psychotherapies. It also appears to have a delayed effect that improves the quality of social relationships and interpersonal skills. It has been shown to reduce acute distress and to prevent relapse and recurrence so long as it is continued or maintained. Treatment combining IPT with medication retains the quick results of pharmacotherapy and the greater interpersonal breadth of IPT, as well as boosting response in patients who are otherwise more difficult to treat. The main problem is that IPT has only recently entered clinical practice and is not widely available to those in need. Cognitive behavior therapy (CBT) also appears to be efficacious in treating depression, and recent studies suggest that it can work for even severe depressions in the hands of experienced therapists. Not only can CBT relieve acute distress, but it also appears to reduce risk for the return of symptoms as long as it is continued or maintained. Moreover, it appears to have an enduring effect that reduces risk for relapse or recurrence long after treatment is over. Combined treatment with medication and CBT appears to be as efficacious as treatment with medication alone and to retain the enduring effects of CBT. There also are indications that the same strategies used to reduce risk in psychiatric patients following successful treatment can be used to prevent the initial onset of depression in persons at risk. More purely behavioral interventions have been studied less than the cognitive therapies, but have performed well in recent trials and exhibit many of the benefits of cognitive therapy. Mood stabilizers like lithium or the anticonvulsants form the core treatment for bipolar disorder, but there is a growing recognition that the outcomes produced by modern pharmacology are not sufficient. Both IPT and CBT show promise as adjuncts to medication with such patients. The same is true for family-focused therapy, which is designed to reduce interpersonal conflict in the family. Clearly, more needs to be done with respect to treatment of the bipolar disorders. Good medical management of depression can be hard to find, and the empirically supported psychotherapies are still not widely practiced. As a consequence, many patients do not have access to adequate treatment. Moreover, not everyone responds to the existing interventions, and not enough is known about what to do for people who are not helped by treatment. Although great strides have been made over the past few decades, much remains to be done with respect to the treatment of depression and the bipolar disorders.

2018 ◽  
Author(s):  
Charles Bowden ◽  
Melissa Martinez

Patients with bipolar disorders spend a greater proportion of their illness in a depressed or mixed state rather than experiencing either mania or hypomania. Over the past 20 years, most major pharmaceutical companies have either reduced or abandoned the research and development of novel psychiatric drugs, exiting the development of new, safe, efficacious, and tolerable treatment regimens for bipolar disorder. Therefore, optimizing the current treatments available is critical. We review studies of the last 15 years that provide guidance relevant to managing the maintenance phase of bipolar disorders. Based on these data, we provide recommendations for effective treatment planning and implementation, principally for the maintenance phase care of persons with bipolar disorder. We also discuss strategies for implementing medication regimens, differentiating strategies for maintenance phase treatment from those of acute phase treatment. Assessing key symptoms that are sensitive to change is critical for longitudinal assessments and treatment planning for patients with bipolar disorders. In most studies, only a subset of rating scale items differentiate patients with good responses from those without. Identified symptoms include racing thoughts, less need for sleep, hyperactivity, increased activity, and increased energy. We developed a procedure for using Multistate Outcome Analysis of Treatment (MOAT) in bipolar disorders. MOAT integrates efficacy and tolerability data during studies to provide information about the quantity and quality of time spent in distinct mood states. The protocol developed will be useful for assessing treatment strategies in bipolar disorder. This review contains 4 figures, 7 tables and 32 references Key words: bipolar, depression, lithium, mania, mixed, mood stabilizer, survival analysis, symptom domains, valproate


2018 ◽  
Vol 19 (10) ◽  
pp. 3026 ◽  
Author(s):  
Charanraj Goud Alladi ◽  
Bruno Etain ◽  
Frank Bellivier ◽  
Cynthia Marie-Claire

So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. Therefore, epigenetics has emerged as a major field of research to study the treatment of these three disorders. Among the epigenetic marks that can modify gene expression, DNA methylation is the best studied. We performed a systematic search (PubMed) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA guidelines for preclinical and clinical studies focused on genome-wide and gene-specific DNA methylation in the context of schizophrenia, bipolar disorders, and major depressive disorder. Out of the 112 studies initially identified, we selected 31 studies among them, with an emphasis on responses to the gold standard treatments in each disorder. Modulations of DNA methylation levels at specific CpG sites have been documented for all classes of treatments (antipsychotics, mood stabilizers, and antidepressants). The heterogeneity of the models and methodologies used complicate the interpretation of results. Although few studies in each disorder have assessed the potential of DNA methylation as biomarkers of treatment response, data support this hypothesis for antipsychotics, mood stabilizers and antidepressants.


2002 ◽  
Vol 36 (7-8) ◽  
pp. 1277-1281 ◽  
Author(s):  
Ian D Maidment

OBJECTIVE: To review data on the effectiveness of topiramate as a mood stabilizer. DATA SOURCES: Clinical literature accessed through MEDLINE (1985–September 2001) and the manufacturer. Key search terms included topiramate, mania, mood stabilizer, and bipolar disorder. DATA SYNTHESIS: The traditional standard therapy for bipolar disorder has been lithium. Other mood stabilizers are increasingly being used to manage this complex disorder. Studies that used topiramate in bipolar disorders were evaluated. CONCLUSIONS: The present data from open trials suggest that topiramate may possibly possess antimanic properties. Controlled, double-blind studies are required to confirm this efficacy.


2019 ◽  
Vol 27 (2 (99)) ◽  
pp. 38-47
Author(s):  
Igor Martsenkovsky ◽  
Inna Martsenkovska

The article presents the features of diag nosis and treatment of schizophrenia and bipolar disorders (BD) with early manifestation in adolescence. Management of disorders includes the complex use of pharmacological, psychological treatment and special forms of social care. The treatment program should include the psychoeducation of the child and his parents and the mobilization of family support. The article also discusses the effi cacy of atypical antipsychotics (risperidone, aripiprazole, olanzapine) and mood stabilizers (valproate, lithium, lamotrigine, and carbamazepine) based on recommendations Food and Drug Administration (FDA) USA, European Medicines Agency (EMA) and the Expert Center of the Ministry of Health of Ukraine. The obtained results of own conducted controlled trials on the effi cacy and safety of olanzapine use are discussed by the authors. Since 2010, 22 cases of olanzapine (Zolafren®) use for adolescents with schizophrenia spectrum disorders aged 13—17 years have been registered in the department of mental disorders of children and adolescents at the Institute of Psychiatry of the Ministry of Health of Ukraine. The period of controlled administration for olanzapine at a dose of 5—20 mg per day ranged from 44 to 70 weeks. As a result of the study were highlighted clinical situations in which the characteristics of the olanzapine action profi le demonstrated its greater effi cacy compared to risperidone and conventional antipsychotics in adolescents. The aim of another controlled trial conducted by the Institute of Psychiatry of the Ministry of Health of Ukraine in 2015—2018 was to evaluate the efficacy of olanzapine at a dose of 5—20 mg per day in adolescents with fi rst time diagnosed acute manic/mixed episode of BD. Nine adolescents aged from 14 to18 years old were assigned. Olanzapine in dose 5 to 20 mg was an eff ective medication for treatment of acute/mixed affective episodes in adolescents with BD and was an acceptable alternative to conventional antipsycho tics and risperidone treatment. Various side eff ects were observed in patients receiving olanzapine therapy, the average number of side eff ects per patient was 2.86, while the most frequent side eff ect was weight gain. Keywords: schizophrenia, bipolar disorder, antipsychotic medication, pediatric practice, children and adolescents


2011 ◽  
Vol 26 (S2) ◽  
pp. 298-298
Author(s):  
M. Huang ◽  
L. Guo ◽  
M. Ran

ObjectiveTo explore the clinical characteristics, assessment, biological and psychosocial correlates, and treatment of pediatric bipolar disorder (BD) in China.MethodAll the studies published during the past 20 years on pediatric bipolar disorder in China were reviewed.ResultsThere is a lack of a unified diagnosis system in China. A serial of genetic researches showed the family aggregation and genetic predisposition of BD. There are consistent findings on the core symptoms of the disorder. BD has the characteristic of comorbidity with other disorders such as ADHD and OCD. Mood stabilizers and combined use of antipsychotics and TCA are still the main choice of psychiatrists to treat the pediatric patients with BD. The effectiveness of specific psychotherapy does need further studies.ConclusionA unified diagnosis system and criteria of BD for different age groups is crucial for further work. Combination of various treatments, such as mood stabilizers, AC, TCA and traditional Chinese medicine is effective for these patients. More studies, especially randomized controlled trials should be conducted to explore the etiology, pharmacotherapy and psychotherapy of this disease.


Author(s):  
Paul E. Keck ◽  
Susan L. McElroy

The vast majority of clinical trials in patients with bipolar disorders have been conducted in groups with bipolar I illness, although a few trials have recently emerged specifically in patients with bipolar II disorder. The pharmacological management of bipolar disorder involves the treatment of acute manic, hypomanic, mixed, and depressive episodes, as well as the prevention of further episodes and subsyndromal symptoms. Lithium, divalproex, carbamazepine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have demonstrated efficacy in the treatment of acute mania in randomized, controlled (Type 1) trials. Although the pharmacological treatment of acute bipolar depression remains understudied, data from randomized, controlled trials indicate that lithium, olanzapine, olanzapine-fluoxetine, quetiapine, lamotrigine, tricyclics, MAOIs, fluoxetine, and pramipexole have efficacy in this phase of the illness. The optimal duration of antidepressant treatment, in combination with mood stabilizers, is still unknown. Lithium, lamotrigine, olanzapine, and aripiprazole have been shown to have efficacy in relapse prevention. Less extensive data suggest that divalproex and carbamazepine are also efficacious as preventative treatments.


Medicina ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 1213
Author(s):  
Martin Schaefer ◽  
Marylou Selo ◽  
Nadja Stehlin ◽  
Barbara Wagenblast ◽  
Thomas Bock

The German concept of a trialogue in medicine is at its best a cooperation between patients, relatives, and professionals as partners on equal footing. Prerequisites, and also the aim of the trialogue, are mutual respect, an open attitude from professionals, and self-confidence from patients and relatives. The expertise of each of these groups is to be strengthened through the trialogue and should benefit all. Trialogue cooperation brings about a change of perspective and promotes mutual understanding. By establishing a therapeutic relationship on equal footing with the patient with involvement of their relatives, individual and family resources can be better utilized, professional assistance can be designed to better meet the patient’s needs, and acceptance of and commitment to treatment can be increased. In addition, early symptoms and new phases of the disease can be recognized earlier and adequate treatment can be initiated more quickly. A favorable course of the disease is thus more likely, and relapses are less likely to present. The use of peers has proven to be quite helpful. The consistently trialogue structure within the German Society for Bipolar Disorder (Deutsche Gesellschaft für Bipolare Störungen e.V./DGBS: Heinrich-Hoffmann-Straße 10, 60528 Frankfurt am Main) as a medical society enables further development of the trialogue on many levels, for example, the drafting and updating of the German guidelines for bipolar disorder with the trialogue in mind.


Author(s):  
Joel Paris

Bipolar disorder is currently undergoing a diagnostic epidemic. This is because proponents of a broad bipolar spectrum, who can be called “bipolar imperialists” see latent bipolarity in a wide spectrum of other diagnoses. Thus bipolar disorders are being overdiagnosed in patients who are depressed, in patients who have affective instability related to personality disorders, and in children who mainly present with irritability. None of these patients demonstrate manic episodes or the hypomanic episodes required to diagnose bipolar-II. There are no biological markers to support this expansion of the original concept of bipolarity. The result has been a vast over-prescription of “mood stabilizers” and antipsychotics, both in adults and in children.


2017 ◽  
Vol 41 (S1) ◽  
pp. S761-S761
Author(s):  
C. Solana ◽  
S. Nascimento ◽  
M. Mendes ◽  
M. Duarte

IntroductionBipolar disorder is a chronic psychiatric illnesses characterized by alternating episodes of mania/hypomania and major depression, or with mixed features. Acute exacerbations and maintenance treatment with appropriate pharmacotherapy are mandatory. Long-term treatment with mood-stabilizing medications is typically required. The incidence of bipolar disorders in women during the primary reproductive years is very high, and the episodes of mania or depression are thought to occur in an estimated 25%–30% of women with bipolar disorder during pregnancy.ObjectivesProvide a clinically focused review of the available information on the effectiveness and safety of the different pharmacotherapies in the treatment of bipolar disorder during pregnancy.MethodsA bibliographic review is made of the pregnancy in bipolar disorder, based on the data published in PubMed.ResultsClinical decision making about the use of mood stabilizers and atypical anti-psychotics by pregnant women can be conceptualized as balancing the competing risks imposed by withholding or stopping pharmacotherapeutic treatment against that of continuing or initiating pharmacotherapy during pregnancy. Some of the most effective pharmacotherapies have been associated with the occurrence of congenital malformations or other adverse neonatal effects in offspring. There is few information about the safety profile and clinical effectiveness of atypical anti-psychotic drugs when used to treat bipolar disorder during pregnancy.ConclusionsTreating women with bipolar disorders during pregnancy is a challenge. There are no uniformly effective or risk-free treatment options. Fully informed decision-making requires the review of the risks of both untreated maternal bipolar disorder and risks associated with potentials interventions.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Sign in / Sign up

Export Citation Format

Share Document